Topical Cetirizine in Androgenetic Alopecia in Females

Launched by CAIRO UNIVERSITY · Jul 17, 2020

Keywords

ClinConnect Summary

Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a hereditary, androgen-dependent, progressive thinning of scalp hair that follows a defined pattern. The disease mechanism is still relatively poorly understood, but involves a strong genetic contribution as well as some environmental input. AGA manifests as a noticeable reduction of scalp hair coverage, shorter miniaturized telogen vellus hair follicles, and significantly slower rates of hair growth. Approximately 6% to 38% of healthy women experience some degree of frontal and frontoparietal hair loss....

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Females with androgenetic alopecia of age 20-50 years.
• • 2. Patients experiencing active hair loss within the last 12 months.
• • 3. Sinclair scale 2, 3 and 4.
• • 4. Patients willing to continue their current regimen of vitamins and nutritional supplements and not start any new vitamins or nutritional supplements for the duration of the study.
• • 5. Patients willing to use a mild non-medicated shampoo and conditioner for the duration of the study.
• • 6. Patients who did not receive topical or systemic treatment for androgenetic alopecia or prostaglandins in the last 6 months.
• Exclusion Criteria:
• • 1. Patients with a chronic dermatological condition (eczema, psoriasis, infection, etc) of the scalp other than FPHL.
• • 2. Subjects who had hair transplants, scalp reduction, current hair weave or tattooing in the target area, which makes it difficult to perform hair count assessment.
• • 3. Subjects who received radiation therapy to the scalp, or has had chemotherapy in the past year.
• • 4. Subjects who have a known underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
• • 5. Subjects with clinical diagnosis of alopecia areata or other non-AGA forms of alopecia.
• • 6. Pregnant or lactating females or planning to become pregnant for the duration of the study.
• • 7. Patients with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.
• • 8. Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a period.
• • 9. The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.
• • 10. Patients using any medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.